

10/554290

JC20 Rec'd PCT/PTO 25 OCT 2009

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : New Application
Applicant : Mark J. Redmond et al.
Filed : Herewith
TC/A.U. : (to be assigned)
Examiner : (to be assigned)

Docket No. : 2315-126
Customer No. : 06449
Confirmation No. :

INFORMATION DISCLOSURE STATEMENT


Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Under the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, Applicant submits herewith information that the Office may wish to consider in examination of the subject application. The publications, which are listed on the attached Form 1449, were cited in an International Search Report (copy attached herewith) in corresponding International Application No. PCT/CA2004/000662.

Respectfully submitted,

By



Jeffrey L. Ihnen
Attorney for Applicants
Registration No. 28,957
ROTHWELL, FIGG, ERNST & MANBECK, p.c.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202)783-6040

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	New Application 10/354290
				Filing Date	Herewith
				First Named Inventor	Mark J. Redmond
				Group Art Unit	
				Examiner Name	
				Confirmation No.	
				Sheet	1

[illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code.

*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	New Application 10/554290
				Filing Date	Herewith
				First Named Inventor	Mark J. Redmond
				Group Art Unit	
				Examiner Name	
				Confirmation No.	
Sheet	2	of	3	Attorney Docket Number	2315-126

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³ Code	Number ⁴	Kind ⁵ (if known)			
		WO	03/054077	A1	Ceapro	07-03-2003	
		WO	02/43719	A2	Glenn H. Weissman	06-06-2002	
		WO	00/67626	A2	Ceapro Inc.	11-16-2000	
		WO	01/74300	A1	Brennen Medical Inc.	10-11-2001	
Examiner Signature						Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	New Application 10/554290
				Filing Date	Herewith
				First Named Inventor	Mark J. Redmond
				Group Art Unit	
				Examiner Name	
				Confirmation No.	
Sheet	3	of	3	Attorney Docket Number	2315-126

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Jan T. Braaten, et al., "Oat β -glucan reduces blood cholesterol concentration in hypercholesterolemic subjects", European Journal of Clinical Nutrition, 1994, Vol. 48, pp. 465-474	
		Alberto Estrada, et al., "Effect of Administration of Oat β -Glucan on Immune Parameters of Healthy and Immunosuppressed Beef Steers", Can J. Vet Res, 1999, Vol. 63, pp. 261-268	
		Alberto Estrada, et al., "Immunomodulatory Activities of Oat β -Glucan <i>in Vitro</i> and <i>In Vivo</i> ," Microbiol. Immunol., Vol. 41, No. 12, 1997, pp. 991-998	
		Nai-Kong V. Cheung, et al., "Orally administered β -glucans enhance anti-tumor effects of monoclonal antibodies", Cancer Immunol. Immunother, 2002, Vol. 51, pp. 557-564	
		Cheol.-Heiu Yun, et al., " β -Glucan, extracted from oat, enhances disease resistance against bacterial and parasitic infections", FEMS Immunology and Medical Microbiology, 2003, Vol. 35, pp. 67-75	
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.